stockrowMoolec Science SA
MLEC Healthcare Biotechnology
Moolec Science SA’s revenue for fiscal 2025 (year ended June 2025) was $333.6 million, up 5,830.7% from fiscal 2024.
- Revenue
- +948.4%
- EPS
- −20.0%
- Free cash flow
- +4.48%
Quarter to December 2025, against a year earlier
Follow MLEC
Alert me
Moolec Science SA (MLEC) EV/Sales
As of 3 November 2026, Moolec Science SA (MLEC) trades at a EV/Sales of 8.4×. Over the past ten years it has ranged from 0.0× (March 2024) to 75.6× (July 2024); the current reading is higher than 72% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.7× | (92.48%) |
| FY2024 | 75.6× | — |
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 6.5× | (32.05%) |
| Sep 2024 | 9.6× | (87.29%) |
| Jun 2024 | 75.6× | 529.92% |
| Mar 2024 | 12.0× | — |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAGX Jaguar Animal Health, Inc. compare | −0.1× |
| BBLG Bone Biologics Corp. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | 0.3× |
| MLEC Moolec Science SA | 8.4× |
| VBIO Valion Bio, Inc. compare | 11.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)